Results 121 to 130 of about 3,943 (171)

Cadherin 17 Nanobody-Mediated Near-Infrared-II Fluorescence Imaging-Guided Surgery and Immunotoxin Delivery for Colorectal Cancer. [PDF]

Biomater Res
Ding Y, Zhou R, Shi G, Jiang Y, Li Z, Xu X, Ma J, Huang J, Fu C, Zhou H, Wang H, Li J, Dong Z, Yu Q, Jiang K, An Y, Liu Y, Li Y, Yu L, Li Z, Zhang X, Wang J.   +21 more
europepmc   +1 more source

Development of Z_HPV16E7- granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death. [PDF]

Front Immunol
Tan X, Yang J, Li Y, Wan K, Feng S, Jing X, Xie Z, Zhang L, Li W.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immunotoxins

Cell, 1986
Ira Pastan, M C Willingham, D J Fitzgerald   +2 more
exaly   +3 more sources

Immunotoxins and nanobody-based immunotoxins: review and update

Journal of Drug Targeting, 2021
Immunotoxins (ITs) are protein-based drugs that compose of targeting and cytotoxic moieties. After binding the IT to the specific cell-surface antigen, the IT internalises into the target cell and kills it. Targeting and cytotoxic moieties usually include monoclonal antibodies and protein toxins with bacterial or plant origin, respectively.
Mohammad Reza Khirehgesh, Jafar Sharifi, Fatemeh Safari, Bahman Akbari   +3 more
openaire   +2 more sources

Immunotoxins: An Update

Annual Review of Immunology, 1996
The use of immunotoxins (ITs) in the therapy of cancer, graft-vs-host disease (GvHD), autoimmune diseases, and AIDS has been ongoing for the past two decades. ITs contain a targeting moiety for delivery and a toxic moiety for cytotoxicity. Theoretically, one molecule of a toxin, routed to the appropriate cellular compartment, will be lethal to a cell ...
G R, Thrush, L R, Lark, B C, Clinchy, E S, Vitetta   +3 more
openaire   +2 more sources

Recombinant immunotoxins

Breast Cancer Research and Treatment, 1996
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
I, Pastan, L H, Pai, U, Brinkmann, D, FitzGerald   +3 more
openaire   +2 more sources

Neurotoxicity of immunotoxins

Molecular and chemical neuropathology, 1994
Immunotoxins are being tested for the therapy of systemic cancer and brain tumors. Neurotoxicity has been dose limiting for several of these antibody conjugates given systemically. We review the animal and clinical data related to the neurotoxicity of immunotoxins in attempt to understand the molecular basis for the unexpected neural involvement and to
O, Ilercil, D W, Laske, S, Walbridge, K, Muaszko, E H, Oldfield, R J, Youle   +5 more
openaire   +2 more sources

CLL immunotoxins

Leukemia Research, 2005
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB(486)IL2, DAB(389)IL2, RFB4 (dsFv ...
Arthur E, Frankel, Robert J, Kreitman
openaire   +2 more sources

Immunotoxins

Expert Opinion on Pharmacotherapy, 2000
Immunotoxins are molecules which contain a protein toxin connected to a targeting antibody. The goal of therapy is for the molecule to bind selectively to cancer cells, or to cells mediating autoimmune disease, internalise and then for the toxin to kill the cell.
openaire   +2 more sources